LP-118 is under clinical development by Newave Pharmaceutical and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LP-118’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LP-118 overview
LP-118 is under development for the treatment of refractory and relapsed non-Hodgkin's lymphoma including marginal zone B-cell lymphoma (MZL), relapsed or refractory B-cell lymphoma and advanced or metastatic solid tumors, diffuse large B cell lymphoma (DLBCL), waldenstrom macroglobulinemia, small lymphocytic lymphoma (SLL), adult T cell lymphoma (ATLL), chronic myelomonocytic leukemia , mantle cell lymphoma, peripheral T-cell lymphomas (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), multiple myeloma, Richter transformation chronic lymphocytic leukemia, T cell prolymphocytic Leukemia, B-cell acute myeloid lymphoma, relapsed and refractory acute lymphocytic leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, unspecified b-cell lymphomas, natural killer cell lymphomas, T-cell lymphomas, T-cell acute lymphoblastic leukemia or T-lymphoblastic lymphoma, small cell lung cancer and myelofibrosis. It is administered through oral route and acts by targeting Bcl-2/Bcl-xl.
Newave Pharmaceutical overview
Newave Pharmaceutical Inc is a clinical stage biopharmaceutical company focus on the development of novel therapies to treat cancer diseases. The company is headquartered in Guangzhou, Guangdong, China.
For a complete picture of LP-118’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
